Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease

Creative Commons License

Yuzbasioglu B., Ustaoğlu Dede M., Yuzbasioglu S., Akbulut U. E., Ozdil K.

TURKISH JOURNAL OF GASTROENTEROLOGY, cilt.30, sa.12, ss.1025-1029, 2019 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 12
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/tjg.2019.19346
  • Dergi Adı: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1025-1029
  • Anahtar Kelimeler: Crohn's disease, thrombophilia, ulcerative colitis, ACTIVATABLE FIBRINOLYSIS INHIBITOR, FACTOR PATHWAY INHIBITOR, TISSUE FACTOR, THROMBOSIS, RISK, COAGULATION, STATE, WOMEN
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Background/Aims: There is an increased tendency for thrombosis and thromboembolic complications in patients with inflammatory bowel disease (IBD). The aim of the present study was to determine the serum concentrations of thrombin-activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI) and a disintegrin and metalloproteinase with thrombospondin motif-13 (ADAMTS-13) in patients with IBD and to assess their possible role in the etiopathogenesis of the disease.